Brief report · 29 Dec 2025
Conference abstractPublished 2 Jul 2012
Commercialization of Biomarkers: Diagnostics and Drug Development
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The commercialization of biomarkers touches on a broad range of scientific areas. In the age of personalized medicine, biomarker analyses are establishing themselves as necessary tools for diagnosis as well as for determining a path for therapy. Screening tests are employed for determining high risk for cancers of the breast, prostate, cervix, and colon. In addition, through companion biomarker analyses, determinations can be made as to the potential effectiveness of treatment (Herceptin, Camptosar, Coumadin). Biomarkers in the contract research organization (CRO) demonstrate how their commercialization is applied to the drug development world. In this realm, biomarker results offer insight into mechanism of action and efficacy, as well as an aid to submission and approval when included in clinical trials. This presentation will touch on concepts of biomarker development for clinical assessment and relay first-hand experience on biomarker analysis for drug development from a CRO perspective.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Michael Sullivan”
